Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
CINCINNATI, OH, March 05, 2018 --
Callitas Health Inc. (CSE: LILY, OTCBB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) a clinical-stage company developing innovative technologies for weight management and female health and wellness, announced today a new partnership with NFI Consumer Healthcare’s e.p.t®, the Over-The-Counter ("OTC") pregnancy test kit brand.
“ToConceive, our clinically proven fertility lubricant, is a perfect cobranding fit with e.p.t. pregnancy test kits, a category leader in the women’s OTC health market,” stated Callitas CEO James Thompson. “e.p.t.’s brand recognition in the space will help our Company build awareness for the fantastic impact ToConceive can have on couples trying to get pregnant.”
The partnership between NFI and Callitas will include promotional opportunities on shelf, product samples and new product inclusion at major food, drug and mass retailers throughout the United States.
“After purchasing EPT in 2017, our group began working on potential line extensions for the brand that would emerge it from only being a pregnancy test brand to becoming part of the complete family planning process,” said Benjamin Blessing, EVP of Sales and Marketing for NFI Consumer Products.
“Developing a packaging concept that included the ToConceive product just made sense to us,” Blessing said. “This is a brand completely devoted to helping women fulfill their desire to become pregnant. We are pleased to have a product that may facilitate a long-anticipated and life changing pregnancy.”
About Callitas Health
Formed in early 2015, Callitas Health Inc. is a clinical-stage company developing innovative technologies for obesity, weight management and female health & wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive. www.toconceive.com.
Callitas Health Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “LILY” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”
For more information contact: James Thompson, CEO, or Callitas Investor Relations Phone: +1 (859) 868-3131 www.callitas.com
